<DOC>
	<DOCNO>NCT00002036</DOCNO>
	<brief_summary>To investigate potential benefit provide passive immunity hyperimmune anti-HIV human serum .</brief_summary>
	<brief_title>Phase I Safety Study Anti-HIV Immune Serum Globulin ( Human )</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immune Sera</mesh_term>
	<criteria>Inclusion Criteria Patients must : Proof HIV infection . Diagnosis asymptomatic HIV infection early AIDS relate complex ( ARC ) zidovudine ( AZT ) antiHIV therapy . OR diagnosis AIDS = &gt; 3 month AZT therapy . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : HIVinduced neurological disease . IgA negative . Concurrent Medication : Excluded : Immunomodulating agent . Steroids . Interferons . Patients follow exclude : Active substance abuse . Use immunomodulating drug steroids interferon . HIVinduced neurological disease . IgA negative . Required diagnosis AIDS : = &gt; 3 month zidovudine ( AZT ) therapy . Active substance abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Immunization , Passive</keyword>
</DOC>